Shenyang Pharma Univ. ROCK2 compound 39

Shenyang Pharma Univ. ROCK2 compound 39: sourced facts only. name: "A dedicated evaluation discovered the optimal compound 39, which exhibited potent ROCK2 inhibition (IC50 = 0.0081 μM), enhanced kinetic solubility (77 μg/mL in water), improved metabolic stability (t1/2 = 5.0 h for p.o), favorable kinase selectivity, and an acceptable safety profile." [PMID:42183679]; target: "A dedicated evaluation discovered the optimal compound 39, which exhibited potent ROCK2 inhibition (IC50 = 0.0081 μM), enhanced kinetic solubility (77 μg/mL in water), improved metabolic stability (t1/2 = 5.0 h for p.o), favorable kinase selectivity, and an acceptable safety profile." [PMID:42183679]; developer: "Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China." [PMID:42183679]; stage: "Notably, 39 effectively suppressed TGF-β1-induced fibroblast activation and migration, while significantly attenuating bleomycin-induced PF in vivo." [PMID:42183679]